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Subclinical hypothyroidism among Egyptian children with systemic lupus 
erythematosus 
INTRODUCTION 
Systemic lupus erythematosus (SLE) is a chronic 
autoimmune disease characterized by 
autoantibodies directed against self-antigens and 
resulting in inflammatory damage to target organs 
including the kidneys, blood cells and central 
nervous system1. 
Thyroid autoimmune diseases have been 
associated with a variety of rheumatological 
diseases, including SLE2. Both hypo- and 
hyperthyroidism are seen in association with SLE, 
but hypothyroidism is more common. Up to 35% of 
pediatric SLE patients have antithyroid antibodies, 
with 10% to 15% of patients developing overt 
hypothyroidism3. 
The vast majority of hypothyroidism in SLE 
results from autoimmune thyroiditis. The 
autoimmune process is believed to begin with 
activation of CD4+T-helper lymphocytes specific 
for thyroid antigens. Activated CD4+T 
lymphocytes recruit cytotoxic (CD8+) T cells as 
well as B cells into the thyroid gland. Thyroid cell 
destruction occurs through multiple mechanisms: 
cytotoxic T cells that induce apoptosis; cytotoxic 
antibodies that fix complement and cause thyroid 
cell lysis; and antibody-dependent cell-mediated 
cytotoxicity involving natural killer cells4. 
 Subclinical hypothyroidism (SCH) is a 
condition characterized by normal thyroid 
hormones' levels (total and unbound thyroxine and 
triiodothyronine) in the presence of elevated TSH 
and absence of symptoms5. SCH is associated with 
a pro-atherogenic dyslipidemias and increased risk 
of cardiovascular disease6. These effects are being 
greater at higher TSH levels7. 
With this as a background, we aimed to study 
the frequency of subclinical hypothyroidism among 
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a group of Egyptian children with SLE, and 




This cross-sectional study was conducted on 40 
children with SLE, fulfilling the revised 
classification criteria of the American College of 
Rheumatology for diagnosis of SLE8 during the 
period from January 2009 to June 2009. The 
children were regularly followed up at the Pediatric 
Allergy and Immunology Clinic, Children's 
Hospital, Ain Shams University. They were 36 
females and 4 males with a female to male ratio 9:1. 
Their ages ranged between 6 and 17 years with a 
mean of 13.6 ± 2.2 years. Their duration of illness 
ranged from 4 to 119 months with a median of 18 
months. 
An informed oral consent was taken from the 
patients and/ or their care givers before enrolment 
in the study. The study protocol gained acceptance 
of the Pediatric Department's Ethical Committee.  
 
Study measurements: 
A- Clinical evaluation was done for each patient 
with special emphasis on therapeutic history mainly 
the dose and duration of steroid therapy and 
assessment of disease activity using the systemic 
lupus erythematosus disease activity index 
(SLEDAI), symptoms suggestive of 
hypothyroidism (pubertal delay, puffy features, 
swelling in neck, cold intolerance, etc….) or 
hyperthyroidism (emotional lability, weight loss, 
and restless sleep, some degree of exophthalmos, 
etc….). Patients with overt thyroid disease were 
excluded. 
B- The   laboratory work up of the study: 
Eight ml venous blood were withdrawn from each 
patient and divided as follows: 2 ml were collected 
in EDTA tubes for CBC (Coulter Corporation, 
HIELAS, Florida, U.S.A), 2 ml were collected on 
sodium citrate for ESR assay (Westergren method) 
and 4 ml were collected in plain sterile tubes and 
allowed to clot then centrifuged, and serum was 
collected and stored at -20°C.  Serum was used for 
the detection of the levels of cholesterol, 
triglycerides, HDL, LDL and creatinine (on 
Synchron CX7 autoanalyzer, Beckman Instruments, 
Brea, California, USA) and  ANA and anti-dsDNA 
by indirect immunofluorescent assay (IMMCO 
Diagnostics, USA), and for the measurement of C3 
using MININEPH™ (Binding Site Group Ltd, 
Birmingham, UK.), free T4 and TSH using the 
Immulite 2000 (solid phase, chemiluminescent 
immunometric assay) and thyroid peroxidase  
autoantibody (anti-TPO-ab) titre by enzyme linked 
immunosorbant assay (ELISA) using (Accu-Bind 
ELISA microwells Monobind Inc. Lake Forest, CA 
92630, USA). A reference curve was used to 
ascertain the concentration of anti-TPO-ab in 
unknown specimen by utilizing several different 
serum references of known antibody activity. The 
presence of anti-TPO-abs is confirmed when the 
serum level exceeds 40 IU/ml9. 
 
Normal FT4 reference values (ng/dl) according to 
the age10: 
            1-5 years: 0.78-2.09 ng/dl. 
            6-10 years: 1.01-2.09 ng/dl. 
            11-15 years: 0.78-2.02 ng/d. 
                                               
Normal TSH reference values (mIU/mL) according 
to the age11: 
            0-10 years:  0.36-6.0 mIU/mL 
            >10 years:  0.4- 4.0 mIU/mL 
 
Statistical analysis: 
Analysis of data was performed by SPSS (statistical 
program for social sciences version 12). Numeric 
data were expressed as mean ± standard deviation 
and median (range) when appropriate, qualitative 
data were expressed as frequency and percentage. 
Mann Whitney test was used to compare between 
two population medians. Spearman rho non 
parametric correlation was used to test correlation 
between quantitative   variables. All tests were 2 
tailed, p-values less than 0.05 were considered 




Frequency of SCH and patient characteristics 
Six (15%) patients were found to have SCH 
while the remaining 34 (85%) patients had normal 
thyroid function; age and sex distribution were 
comparable between SLE patients with SCH and 
those with normal thyroid function. The 
characteristics of the 2 subgroups are shown in 
table 1. 
Anti-TPO-abs in the 2 subgroups 
Anti-TPO-ab positivity was detected in 4 out of the 
6 (66.6 %) SLE patients with SCH and in 20 out of 
the 34 (58.8%) SLE patients with normal thyroid 
function. There was no statistically significant 
difference in the anti-TPO-ab titre between SLE 
patients with normal thyroid function and those 
with SCH (table 1). Worth mentioning is that the 
titre of anti-TPO-abs although correlated positively 
yet insignificantly with the level of TSH among 
lupus patients with SCH (r=0.67, p=0.17). 
Subclinical hypothyroidism and pediatric lupus. 
 89
The impact of disease activity as assessed by 
SLEDAI on thyroid function  
SLEDAI was comparable in the two groups: SLE 
patients with SCH and those with normal thyroid 
function (table 1). Of the 6 patients with SCH, 3 
had mild activity (SLEDAI <6) and the remaining 3 
had moderate activity (SLEDAI <12). 
The lipid profile of the two subgroups 
Lupus patients with SCH had borderline 
significantly higher serum cholesterol but 
comparable serum triglycerides, HDL and LDL to 
those with normal thyroid function (table 1). Of the 
6 patients with SCH, 4 (66.6%) had hyper-
cholesterolemia with a median (range) of 287 (270-
300), while 6 (18%) patients of those with normal 
thyroid function had hypercholesterolemia with a 
median (range) of 314 (285-364) and only one 
(0.03%) had mild hypertriglyceridemia (179 mg/dl). 
The lipid profile (serum cholesterol, triglycerides, 
HDL and LDL) of SLE patients with SCH 
correlated insignificantly with their thyroid function 
(TSH and FT4) and the anti-TPO-ab titre (table 2). 
Disease characteristics and SCH 
TSH levels correlated positively yet insignificantly 
with   the duration of SLE (r= 0.7, p= 0.12). While, 
anti-TPO-ab titre had borderline significant 
correlation with SLE duration (r= 0.81, p=0.05). 
Both TSH levels and anti-TPO-ab titre did not vary 
significantly with the SLEDAI or the cumulative 
steroids dose (table 3).  
 
Table 1. Demographic and laboratory data of the studied SLE patients. 
 SLE patients with  
normal thyroid function (n=34) 





Mean ± SD 
 
6-17 
13.5 ± 2.21 
 
10-17 
14.3 ± 2.4 
0.4 
Sex   Female 
         Male 
30 (88.2%) 




SLEDAI Score Median (Range) 4.5 (0-10) 5 (2-7) 0.93 
Duration of the disease (months) 
Median (Range) 18(4-119) 19 (7-72) 
 
0.84 
Cumulative steroid dose (grams) 
Median (Range) 10.5 (1-107) 14.9 (5-22) 
 
0.57 
ESR Median (Range) 46 (7-130) 68 (40-96) 0.16 
ANA    Positive 







Median (Range) 206 (10-678) 257 (158-416) 0.57 
C3 (N: 89-189) Median (Range) 90 (27-246) 116 (30-184) 0.9 
Free T4 (ng/dl) Median (Range) 1.4 (0.5-2.0) 1.6 (1-2) 0.16 
TSH (mlu/ml) 
Median (Range) 
Mean ± SD 
 
2.5 (0.33-4) 
2.67 ± 1.03 
 
4.5(4.4-4.9) 
4.56 ± 0.17 
<0.001 










S.CHOL (N: 150-250 mg/dl) 
Median (range) 
Mean ± SD 
202 (130-364) 
222.2 ± 53.3 
277 (207-300) 
260.33 ± 41.31 
0.05 
TG (N: 65-165 mg/dl) 
Median (range) 






HDL (N: > 35 mg/dl) 
Median (range) 






LDL (N: 70-188 mg/dl) 
Median(range) 
Mean ± SD 
144 (70-188) 
142.2 ± 30 
152 (105-185) 
151.16 ± 29.53 
0.47 
SLE: Systemic lupus erythematosus, SLEDAI: Systemic lupus erythematosus disease activity index score, ESR: Erythrocyte 
sedimentation rate, C3: complement-3, Anti-dsDNA: Anti-double stranded DNA, ANA: Antinuclear antibodies, Free T4: Free 
thyroxine hormone, TSH: Thyroid stimulating hormone, anti-TPO-ab: Anti-thyroid peroxidase antibody, S.CHOL: Serum 
cholesterol, TG: Triglycerides, HDL: High density lipoproteins, LDL: Low density lipoproteins, SD: Standard deviation. 
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Table 2. The relationship between the lipid profile (serum cholesterol, 
triglycerides, HDL and LDL) and TSH, FT4 and anti-TPO-ab titre 
among SLE patients with subclinical hypothyroidism. 
TSH 
(mIu/ml) 





r p r p r p 
S. CHOL (mg/dl) 0.21 0.68 -0.08 0.87 0.46 0.35 
S.TG (mg/dl) 0.15 0.77 0.6 0.21 -0.2 0.7 
S. HDL (mg/dl) -0.69 0.12 -0.43 0.38 -0.23 0.66 
S. LDL (mg/dl) 0.03 0.95 -0.08 0.87 0.32 0.54 
S.CHOL: Serum cholesterol, S.TG: Serum triglycerides, S. HDL: Serum high density 
lipoproteins, S.LDL: Serum low density lipoproteins. Free T4: Free thyroxine 
hormone, TSH: Thyroid stimulating hormone, anti-TPO-ab: Anti-thyroid peroxidase 
antibody. P>0.05: non-significant 
 
 
Table 3. The correlation between thyroid profile (TSH & FT4) and 
anti-TPO-ab titre of SLE patients with subclinical hypothyroidism 
and their SLEDAI score and cumulative oral prednisone dose. 
SLEDAI 
Cumulative steroids  
dose (grams)  
r p r p 
TSH (mIu/ml) 0.47 0.35 -0.19 0.73 
Free T4 (ng/dl) -0.03 0.96 -0.2 0.7 
Anti-TPO-ab titre (Iu/ml) 0.57 0.24 0.25 0.63 
SLEDAI: Systemic lupus erythematosus disease activity index, Free T4: Free 
thyroxine hormone, TSH: Thyroid stimulating hormone, anti-TPO-ab: Anti-thyroid 




In this series, six SLE patients (15%) had SCH, 
none had subclinical hyperthyroidism. A number of 
previous studies reported that the prevalence of 
subclinical hypothyroidism among adult SLE 
patients were 13%, 5.7%, 10%, 10%, 13.7%, 11.5% 
and 12% respectively12-18. 
In the present study, the increased frequency of 
anti-TPO-ab positivity among lupus patients   
whether those with SCH or those with normal 
thyroid function suggests that anti-TPO-abs might 
have a pathogenic role in thyroid dysfunction in 
lupus children. It might herald the development of 
autoimmune thyroid disease in those with normal 
thyroid function, but this remains to be verified 
with longitudinal follow up studies. Another 
possibility is that anti-TPO-abs might be a part of 
the polyclonal hypergammaglobulinemia observed 
in lupus patients. It has been reported that 
antithyroglobulin and antimicrosomal (anti-TPO) 
antibodies were present in two thirds of patients 
with clinical or laboratory evidence of thyroid 
disease, but antibodies to thyroglobulin and 
microsomes were present, respectively, in 30% and 
60% of euthyroid children with SLE3. The 
frequency of anti-TPO-abs observed in our studied 
children with SLE seems   similar to that in their 
adult counterparts where a previous study showed 
that 70% of the studied adult SLE patients who 
developed autoimmune thyroid disease at follow-up 
had previously positive thyroid antibodies17. Also, 
the frequency of anti-TPO-abs in patients with 
autoimmune thyroid disease was found to be about 
85%-100%19. However, the prevalence of anti-
TPO-abs in previous studies conducted on adult 
SLE patients  were found to be 27%, 23.2%, 3.7%, 
15%, 25.6%, respectively12-14,16,20. 
In this study, anti-TPO-ab titre correlated 
positively, albeit insignificantly with the levels of 
TSH among SLE patients with SCH. This suggests 
that the former is directly involved in thyroid injury 
with subsequent thyroid dysfunction and elevated 
TSH levels. The lack of significance could be 
attributed to the small sample size. 
The subclinical hypothyroidism observed in 
two of the studied SLE patients with negative anti-
TPO-abs suggest that other mechanisms might 
come into play, possibly anti-thyroglobulin 
antibodies,  immune mediated thyroid injury 
through other mechanisms or non-immune thyroid 
injury. 
This study revealed that SLE activity as 
measured by SLEDAI did not affect the thyroid 
profile (TSH and FT4) and anti-TPO-ab titre of 
Subclinical hypothyroidism and pediatric lupus. 
 91
studied SLE patients with SCH. This can be 
explained by the fact that SLE flare affects different 
organ variably. Therefore, disease activity does not 
necessarily affect the thyroid gland. This was in 
accordance with previous studies which found no 
significant correlation between lupus flare and titre 
of thyroid autoantibodies and thyroid function (FT4 
and TSH) among their studied adult lupus 
patients15,17,21,22. Also, SLE disease activity did not 
predict the occurrence of hypothyroidism in adult 
lupus patients16. 
Other studies reported an association between 
thyroid autoimmunity and disease activity in SLE. 
This was explained in part by the effect of 
interferons, where elevated interferons, during 
flares of SLE activity, might lead to aberrant major 
histocompatibility complex (MHC) expression by 
thyrocytes, provoking an autoimmune response and 
the development of antithyroid antibodies23-25. Also, 
the fluctuating course of thyroid autoimmunity 
observed among a group of adult lupus patients was 
attributed to the variation of thyroid autoantibodies 
with SLE activity21. 
 In the present study, the duration of SLE 
correlated positively with borderline significance 
with anti-TPO- ab titre but insignificantly with TSH 
levels. Small sample size could interfere with 
displaying the actual relationship between SLE 
duration and thyroid function and autoimmunity. 
Longer duration of SLE would give the altered 
immune system a greater chance to react against 
different organs with subsequent organ dysfunction 
in variable severity ranging from subtle 
biochemical disturbance to overt clinical disease. 
This was in agreement with a previous study in  
adult patients with lupus26. Another two studies in 
adults could not demonstrate such an effect16,18. 
The cumulative dose of oral prednisone given 
to the subgroup of studied SLE patients with SCH 
did not affect the thyroid function or the anti-TPO-
ab titre. The effect of corticosteroids is controlled 
by its pharmacogenetics which has individual and 
ethnic variation. Inter-ethnic differences in 
glucocorticoids (GCs) response have been observed 
clinically27, and the prevalence of many GC-
regulated physiological traits differs across human 
populations28. Therefore, it seems that our lupus 
patients escaped the GC-induced thyroid 
dysfunction but larger sample and longer duration 
are needed to verify this suggestion.  Similar results 
have been previously reported   among adult lupus 
patients17. 
The SCH observed in 6 of our studied SLE 
children appeared to have borderline association 
with hypercholesterolemia supporting the role of 
thyroid gland in lipid metabolism particularly LDL 
and cholesterol clearance. Similarly other studies 
reported that elevations in TSH above the normal 
range was significantly correlated with increasing 
LDL and possibly serum cholesterol levels which 
might cause or contribute to a pro-atherogenic 
lipids level29,30. A possible explanation is the 
younger age of our studied SLE patients, and lack 
of follow up period which would not allow for the  
effects of thyroid dysfunction to be revealed. 
 Our study has some limitations due to small 
sample size and  lack of follow up period   that 
would otherwise reveal the actual prevalence of 
SCH among juvenile onset lupus and its adverse 
long term effects on serum lipids. 
In conclusion, SCH is observed in up to 15% of 
children with SLE. SCH does not seem to affect 
serum lipids. Further studies are needed to delineate 
the long term effects of subclinical hypothyroidism 
among SLE patients and hence to evaluate the need 
for thyroxine replacement therapy. The role of anti-
TPO-abs in prediction of immune mediated thyroid 
disorders among pediatric SLE warrants 




1. Klein MS, Miller ML. Systemic Lupus 
Erythematosus. In: Behrman RE, Kleigman RM, 
Jenson HB (eds). Nelson Textbook of Pediatrics, 
17th ed.  Philadelphia: W B Saunders Inc, 2004. p. 
809-13. 
2. Viggiano DP, Saliva NA, Montandon AC, 
Barbosa VD. Prevalence of thyroid autoimmune 
disease  in patients with systemic lupus 
erythematosus. Arq Bras Endocrinal Metab  2008; 
52: 531-6 (Abstract). 
3. Eberhard BA, Laxer RM, Eddy AA, Silverman 
ED. Presence of thyroid abnormalities in children 
with systemic lupus erythematosus.  J Pediatr 1991; 
119:  277-9. 
4. Weetman AP. Chronic  autoimmune  thyroiditis. 
In: Braverman LE, Utiger RD (editors). The 
Thyroid: A Fundamental and Clinical Text, 8th ed. 
Philadelphia: Lippincott Williams and Wilkins, 
2000. p. 721-32. 
5. McDermott MT, Ridgway EC. Subclinical 
hypothyroidism is mild thyroid failure and should be 
treated. J Clin Endocrinol Metab 2001; 86:  4585-90. 
6. Chu JW, Crapo LM. Should mild subclinical 
hypothyroidism be treated? Am J Med 2002; 112: 
422–3. 
7. Kahaly GJ. Cardiovascular  and atherogenic 
aspects of subclinical hypothyroidism. Thyroid 
2000; 10: 665-79. 
El-Ghoneimy et al. 
92 
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane 
DJ, Rothfield NF, et al. The 1982 revised criteria 
for the classification of systemic lupus 
erythematosus. Arthritis Rheum 1982;  25: 1271-7. 
9. Degroot LJ. Heterogenicity  of human antibodies 
to TPO thyroperoxides. Thyroid Autoimmunity 
1990; 207: 177-82. 
10. Hay ID, Bayer MF. American thyroid association 
assessment of current free thyroid hormone and 
thyrotropin measurements and guidelines for future 
clinical assays. Clin chem 1991; 37:  2002-8. 
11. Baloch Z, Carayon P, Conte-Devolex B, Demer 
LM, Feldt-Rasmussen U, Henry JF, et al. 
Guidelines Committee, National Academy of 
Clinical Biochemistry (NACB). Laboratory 
medicine practice guidelines (LMPG). Laboratory 
support for the diagnosis and monitoring of thyroid 
disease. Thyroid 2003; 13(1): 3-126. 
12. Chan A'I'Y, Soffhr AL, Bucknall RC. Thyroid 
disease in systemic lupus erythematosus and 
rheumatoid arthritis. Rheumatology 2001; 4: 353-4. 
13. Pyne D, Isenberg DA. Autoimmune thyroid 
disease in systemic lupus erythematosus. Ann 
Rheum Dis 2002; 61: 70-2. 
14. El-Sherif WT, El Gendi SS, Ashmawy MM. 
Thyroid disorders and autoantibodies in systemic 
lupus erythematosus and rheumatoid arthritis 
patients. Egypt J Immunol 2004; 11: 81-90. 
15. Kakehasi AM, Dias VN, Duarte JE,   Lanna 
CCD, de Carvalho MAP. Thyroid abnormalities in 
systemic lupus erythematosus: a study in 100 
Brazilian patients. Rev Bras Reumatol 2006; 46: 
375-9. 
16. Al-Saleh J, Jassim V, El-Sayed M, Saleh N, 
Harb D. Clinical and immunological manifestations 
in 151 SLE patients living in Dubai. Lupus 2008; 
17: 62–6. 
17. Appenzeller S, Pallone AN, Natalin RA, 
Costallat LT.  Systemic lupus erythematosus, 
thyroid dysfunction, autoimmunity. J Clin 
Rheumatol 2009; 15: 117–9. 
18. Kumar K, Kole AK, Karmakar PS, Ghosh A. The 
spectrum of thyroid disorders in systemic lupus 
erythematosus. Rheumatol Int 2010; doi: 
10.1007/s00296-010-1556-50. 
19. Engler H, Staub JJ, Althaus B.  Assessment of 
antithyroglobulin and microsomal autoantibodies in 
patients with autoimmune thyroid disease: 
comparison of haemagglutination assay, enzyme-
linked immunoassay and radioligand assay. Clinica 





20. Park DJ, Cho CS, Lee SH, Park SH, Kim HY. 
Thyroid disorders in Korean patients with systemic 
lupus erythematosus. Scand J Rheumatol 1995; 
1:13–7. 
21. Kausman D, Isenberg DA. Thyroid autoimmunity 
in systemic lupus erythematosus: the clinical 
significance of a fluctuating course. Br J Rheumatol 
1995; 34: 361- 4. 
22. Mader R, Mishail S, Adawi M, Lavi I, 
Luboshitzky R. Thyroid dysfunction in patients 
with systemic lupus erythematosus (SLE): relation 
to disease activity. Clin Rheumatol 2007; 11: 1891– 
4. 
23. Ytterberg SR, Schnitzer TJ. Serum interferon 
levels in patients with systemic lupus erythematosus. 
Arthritis Rheum1982; 25: 401-6. 
24. Kim T, Kanayama Y, Negoro N, Okamura M, 
Takeda T, Inoue T.  Serum levels of interferons in 
patients with systemic lupus erythematosus. Clin 
Exp Immunol 1987; 70:  562-9. 
25. Magaro M, Zoli A, Altomonte L. The association 
of silent thyroiditis with active systemic lupus 
erythematosus. Clin Exp Rheumatol 1992; 10:  67-
70. 
26. Tsai RT, Chang TC, Wang CR, Chuang CY, Chen 
CR. Thyroid disorders in Chinese patients with 
systemic lupus erythematosus. Rheumatol Int 1993; 
l3: 9-13. 
27. Mattano LA, Jr., Sather HN, Trigg ME, 
Nachman JB. Osteonecrosis as a complication of 
treating acute lymphoblastic leukemia in children: a 
report from the Children’s Cancer Group. J Clin 
Oncol 2000; 18: 3262–72. 
28. Lin SX, Carnethon M, Szklo M, Bertoni A. 
Racial/ethnic differences in the association of 
triglycerides with other metabolic syndrome 
components: the Multi-Ethnic Study of 
Atherosclerosis. Metab Syndr Relat Disord 2011; 9: 
35–40. 
29. Meier C, Staub JJ, Roth CB, Guglielmetti M,  
Kunz M, Miserez AR, et al. TSH-controlled l-
thyroxine therapy reduces cholesterol levels and 
clinical symptoms in subclinical hypothyroidism: a 
double-blind, placebo-controlled trial (Basal Thyroid 
Study). J Clin Endocrinol Metab 2001; 86: 4860-6. 
30. Ineck BA, Ng TM.  Effects of subclinical 
hypothyroidism and its treatment on serum lipids. 
Ann Pharmacotherapy 2003; 37: 725–30. 
